IPP Bureau
Dabur's NewU signs Unicommerce to power its omnichannel operations
By IPP Bureau - September 10, 2025
Schneider Electric and Apollo Hospitals collaborate for energy-efficient healthcare solutions
By IPP Bureau - September 10, 2025
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Botanic Healthcare launches Rs. 25 crore liposomal manufacturing facility in Hyderabad
By IPP Bureau - September 10, 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Evonik and Ethris partner to expand offerings for nucleic acid delivery
By IPP Bureau - September 10, 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
By IPP Bureau - September 10, 2025
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Novartis to acquire Tourmaline Bio for $1.4 billion
By IPP Bureau - September 10, 2025
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
SPL Infusion commences commercial production of new IV fluid Infusion plant
By IPP Bureau - September 09, 2025
The facility has been designed with a dual focus on efficiency and sustainability
Ichnos Glenmark Innovation receives upfront payment of $700 million from AbbVie
By IPP Bureau - September 09, 2025
The payment is in accordance with the agreed contractual terms
Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery
By IPP Bureau - September 09, 2025
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
Congruence gets $32 million financing to advance genetic obesity candidate drug
By IPP Bureau - September 09, 2025
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions
By IPP Bureau - September 09, 2025
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Gilead Sciences breaks ground on new manufacturing and technical development site in US
By IPP Bureau - September 09, 2025
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
By IPP Bureau - September 09, 2025
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
FDA grants Fast Track Designation for Teva’s Emrusolmin
By IPP Bureau - September 09, 2025
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
By IPP Bureau - September 08, 2025
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
